Perrigo Company plc Foreign Currency Transaction Gain (Loss), before Tax
Perrigo Company plc (PRGO) reported Foreign Currency Transaction Gain (Loss), before Tax of $0 for the 12-month period ending 2024-12-31, per its 10-K filed 2025-02-28.
Financial Statements › Income Statement › Other Income
us-gaap:ForeignCurrencyTransactionGainLossBeforeTax · last filed 2025-02-28
- Perrigo Company plc foreign currency transaction gain (loss), before tax for the quarter ending 2023-12-31 was $0.00.
- Perrigo Company plc foreign currency transaction gain (loss), before tax for the quarter ending 2023-09-30 was $0.00.
- Perrigo Company plc foreign currency transaction gain (loss), before tax for the quarter ending 2022-12-31 was $0.00.
- Perrigo Company plc foreign currency transaction gain (loss), before tax for the quarter ending 2022-10-01 was $0.00.
- Perrigo Company plc foreign currency transaction gain (loss), before tax for fiscal 2024 was $0.00.
- Perrigo Company plc foreign currency transaction gain (loss), before tax for fiscal 2023 was $0.00.
- Perrigo Company plc foreign currency transaction gain (loss), before tax for fiscal 2022 was -$39.40M.
- Perrigo Company plc foreign currency transaction gain (loss), before tax for fiscal 2021 was $0.00.
| Period end | Foreign Currency Transaction Gain (Loss), before Tax 3 month | Foreign Currency Transaction Gain (Loss), before Tax 6 month | Foreign Currency Transaction Gain (Loss), before Tax 9 month | Foreign Currency Transaction Gain (Loss), before Tax 12 month |
|---|---|---|---|---|
| 2024-12-31 | $0.00 10-K · filed 2025-02-28 | |||
| 2023-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-28 | $0.00 derived: sum of 2 quarters · filed 2025-02-28 | $0.00 10-K · filed 2025-02-28 | |
| 2023-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-07 | $0.00 10-Q · filed 2023-11-07 | ||
| 2023-07-01 | $0.00 10-Q · filed 2023-08-08 | |||
| 2022-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-28 | $0.00 derived: sum of 2 quarters · filed 2025-02-28 | -$39.40M 10-K · filed 2025-02-28 | |
| 2022-10-01 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-07 | -$39.40M 10-Q · filed 2023-11-07 | ||
| 2022-07-02 | -$39.40M 10-Q · filed 2023-08-08 | |||
| 2021-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-27 | $0.00 derived: sum of 2 quarters · filed 2024-02-27 | $0.00 10-K · filed 2024-02-27 | |
| 2021-10-02 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-08 | $0.00 10-Q · filed 2022-11-08 | ||
| 2021-07-03 | $0.00 10-Q · filed 2022-08-09 | |||
| 2020-12-31 | $0.00 10-K · filed 2023-02-28 | |||
| 2013-09-28 | $4.00 10-Q · filed 2013-11-04 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| NEKTAR THERAPEUTICS (NKTR) | United States | $2.026B | -9.05 |
| Generate Biomedicines, Inc. (GENB) | United States | $2.052B | |
| UroGen Pharma Ltd. (URGN) | $2.015B | -18.42 | |
| Nuvation Bio Inc. (NUVB) | United States | $2.007B | -13.12 |
| Biohaven Ltd. (BHVN) | United States | $1.990B | -3.83 |
| Trevi Therapeutics, Inc. (TRVI) | United States | $2.091B | -51.93 |
| PALVELLA THERAPEUTICS, INC. (PVLA) | United States | $2.105B | -35.55 |
| Braveheart Bio, Inc. (BRVE) | United States | $2.106B | |
| Bausch Health Companies Inc. (BHC) | $2.113B | -1.68 | |
| AGIOS PHARMACEUTICALS, INC. (AGIO) | United States | $1.962B | -5.38 |